This peptide sequence has residues 438-458 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the N-terminus.
96 - well Overlapping Peptide Library Spike glycoprotein from SARS - CoV - 2
5 µmol
Anaspec
Specifications: Spike glycoprotein from SARS-CoV-2: NCBI the RefSeq (YP_009724390.1) of 1273 aa Peptide length: 15 aa, 9aa for the C-terminal peptide. Gross peptide weight: not quantified Synthesis scale: 5 µmol Offset number: 7 aa Format: lyophilized in 96-well plate (P-DW-20-C Axygen®) Counter ion: TFA QC validation: MALDI-TOF QC on 10 % of peptides Coronavirus Spike glycoproteins mediate the virus attachment to host cell surface receptors and facilitate the virus entry by assisting fusion between viral and host cell membranes. They are composed of two subunits, S1 and S2. The Spike protein of SARS-CoV-2 harbors furin cleavage sites, one being located at the boundary between S1 and S2. Spike glycoproteins are extensively studied as targets for antibodies, vaccine candidates or protease inhibitors, as examples. We developed a peptide library spanning the entire Spike glycoprotein from SARS-CoV-2. The library is provided in a convenient 96-well plate format adapted for screening purposes.
The viral genome of the SARS-CoV-2 virus encodes a main protease, 3CLpro (also called nsp5 or Mpro). The proteolytic activity of 3CLpro is needed for viral replication. This peptide substrate serves as a generic peptide substrate for 3CLpro enzymes based on the site-specific cleavage sequence for many coronavirus 3CLpro enzymes. It can be used to measure the activity of the enzyme. This is a FRET peptide where in its intact form, the fluorescence of HiLyte™ Fluor 488 is quenched by QXL® 520. Upon cleavage of the FRET peptide by the active enzyme, the increase of fluorescence can be continuously monitored at excitation/emission = 490/520 nm. With superior fluorescence quantum yield and longer emission wavelength, the HiLyte™ Fluor 488/QXL® 520 based FRET peptide has less interference from the autofluorescence of test compounds and cellular components and provides better assay sensitivity.
pro - NPY peptide (34 - 43), human QXL®520 - RQRYGKRSSP - K(5 - FAM) - NH2
0.1 mg
Anaspec
This peptide corresponds to host derived pro-NPY sequence with a cathepsin cleavage site. Host proteases, such as cathepsin L are involved in the processing and biosynthesis of neuropeptides including pro-NPY. In viral propagation, cathepsin mediated cleavage of viral proteins is necessary for cell entry, thereby affecting the host protein derived pro-NPY. The peptide is labeled with QXL®520 and 5-FAM as FRET pair and thus can serve as a substrate for investigation enzyme cleavage. Neuropeptide Y (NPY) functions as a peptide neurotransmitter and as a neuroendocrine hormone. The active NPY peptide is generated in secretory vesicles by proteolytic processing of pro-NPY.
This peptide from the Spike (S) protein of SARS-CoV is a naturally processed epitope shown to induce specific CTLs. The peptide epitope was validated in binding assay to HLA-A2 of T2 cell line. It also induced specific CD8+ T-cell responses against SARS-CoV. This peptide sequence is also seen within the spike glycoprotein of SARS-CoV2.
The SARS-CoV T-cell peptide antigens set contains 5 peptides corresponding to SARS-CoV spike protein sequence. The sequences have been tested for HLA binding with SARS-CoV protein and includes a positive and a negative control. CV1, CV2 and CV3 sequences are also seen within the spike glycoprotein of SARS-CoV2. The peptide sequences are offered in net peptide quantities in individual vials of 0.25 mg each. The peptide epitopes can be used in ELISPOT, cytokine and CTL assays. The sequences in the set are, CV1- VLNDILSRL CV2- NLNESLIDL CV3- FIAGLIAIV CV4- KLPDDFMGCV (+ve control) CV5- AYRPPNAPIL (-ve control)
This peptide sequence represents residues 319-335 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 319-335 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 336-347 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 336-347 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 348-357 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 348-357 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 352-365 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 352-365 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 371-394 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 371-394 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 395-430 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 395-430 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 513-520 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 513-520 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 523-541 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 523-541 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence has residues 438-458 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2.
This peptide sequence has residues 450-473 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2.
This peptide sequence has residues 450-473 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus
This peptide sequence has residues 480-496 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2.
This peptide sequence has residues 480-496 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence has residues 500-509 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2.
This peptide sequence has residues 500-509 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
Identified from in silico studies, the set of 6 peptides offered are unique T-cell epitopes from the SARS-CoV-2 spike protein sequence. The peptide sequences are offered in net peptide quantities in individual vials of 0.25 mg each. The sequences in the set are, CV2-1 YLQPRTFLL CV2-2 GVYFASTEK CV2-3 KLPDDFTGCV CV2-4 SIIAYTMSL CV2-5 NYNYLYRLFR CV2-6 GYLQPRTFLL
This peptide sequence represents a furin-like cleavage site of the Spike (S) protein of the SARS-CoV-2 virus. The S protein must be likely cleaved at two sites, S1/S2 and S2 for viral entry into host cell. The sequence at the S1/S2 junction which contains a polybasic cleavage site (RR↓AR) represents the first cleavage site. This peptide has been labeled with QXL®520 and 5-FAM.
This peptide sequence represents a second furin-like cleavage site of the Spike (S) protein also thought to participate in the process of viral entry into host cell. The sequence at the S2 site (KR↓SF) contains two basic residues (P1 and P2) and a hydrophobic P3 residue. This site is identical between the SARS-CoV-2 and SARS-CoV. This peptide has been labeled with QXL®520 and 5-FAM.
Beclin-1 peptide is the HIV-1 Nef binding portion of full-length human Beclin-1 protein (amino acids 267-299). Beclin-1 protein is an autophagy inducing agent that may trigger cellular adaptation, survival or cell death. When conjugated to the cell-permeable peptide, it can successfully enter cells and induce autophagy. RELATED PRODUCTS:Beclin-1, Cat# 65466Tat-Beclin-1, scrambled, Cat# 65468
Tat - Beclin - 1, scrambled YGRKKRRQRRRGGVGNDFFINHETTGFATEW
1 mg
Anaspec
Beclin-1 peptide is the HIV-1 Nef binding portion of full-length human Beclin-1 protein (amino acids 267-299). Beclin-1 protein is an autophagy inducing agent that may trigger cellular adaptation, survival or cell death. When conjugated to the cell-permeable peptide, it can successfully enter cells and induce autophagy. Tat-Beclin-1, scrambled will not induce autophagy and can be used as a negative control. RELATED PRODUCTS:Tat-Beclin-1, Cat# 65467Beclin-1, Cat# 65466
This peptide sequence has residues 438-458 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the N-terminus.
96 - well Overlapping Peptide Library Spike glycoprotein from SARS - CoV - 2
Cat No.
EG-COV19-LIB1
규격
5 µmol
제조사
Anaspec
제품정보
Specifications: Spike glycoprotein from SARS-CoV-2: NCBI the RefSeq (YP_009724390.1) of 1273 aa Peptide length: 15 aa, 9aa for the C-terminal peptide. Gross peptide weight: not quantified Synthesis scale: 5 µmol Offset number: 7 aa Format: lyophilized in 96-well plate (P-DW-20-C Axygen®) Counter ion: TFA QC validation: MALDI-TOF QC on 10 % of peptides Coronavirus Spike glycoproteins mediate the virus attachment to host cell surface receptors and facilitate the virus entry by assisting fusion between viral and host cell membranes. They are composed of two subunits, S1 and S2. The Spike protein of SARS-CoV-2 harbors furin cleavage sites, one being located at the boundary between S1 and S2. Spike glycoproteins are extensively studied as targets for antibodies, vaccine candidates or protease inhibitors, as examples. We developed a peptide library spanning the entire Spike glycoprotein from SARS-CoV-2. The library is provided in a convenient 96-well plate format adapted for screening purposes.
The viral genome of the SARS-CoV-2 virus encodes a main protease, 3CLpro (also called nsp5 or Mpro). The proteolytic activity of 3CLpro is needed for viral replication. This peptide substrate serves as a generic peptide substrate for 3CLpro enzymes based on the site-specific cleavage sequence for many coronavirus 3CLpro enzymes. It can be used to measure the activity of the enzyme. This is a FRET peptide where in its intact form, the fluorescence of HiLyte™ Fluor 488 is quenched by QXL® 520. Upon cleavage of the FRET peptide by the active enzyme, the increase of fluorescence can be continuously monitored at excitation/emission = 490/520 nm. With superior fluorescence quantum yield and longer emission wavelength, the HiLyte™ Fluor 488/QXL® 520 based FRET peptide has less interference from the autofluorescence of test compounds and cellular components and provides better assay sensitivity.
pro - NPY peptide (34 - 43), human QXL®520 - RQRYGKRSSP - K(5 - FAM) - NH2
Cat No.
AS-65602
규격
0.1 mg
제조사
Anaspec
제품정보
This peptide corresponds to host derived pro-NPY sequence with a cathepsin cleavage site. Host proteases, such as cathepsin L are involved in the processing and biosynthesis of neuropeptides including pro-NPY. In viral propagation, cathepsin mediated cleavage of viral proteins is necessary for cell entry, thereby affecting the host protein derived pro-NPY. The peptide is labeled with QXL®520 and 5-FAM as FRET pair and thus can serve as a substrate for investigation enzyme cleavage. Neuropeptide Y (NPY) functions as a peptide neurotransmitter and as a neuroendocrine hormone. The active NPY peptide is generated in secretory vesicles by proteolytic processing of pro-NPY.
This peptide from the Spike (S) protein of SARS-CoV is a naturally processed epitope shown to induce specific CTLs. The peptide epitope was validated in binding assay to HLA-A2 of T2 cell line. It also induced specific CD8+ T-cell responses against SARS-CoV. This peptide sequence is also seen within the spike glycoprotein of SARS-CoV2.
The SARS-CoV T-cell peptide antigens set contains 5 peptides corresponding to SARS-CoV spike protein sequence. The sequences have been tested for HLA binding with SARS-CoV protein and includes a positive and a negative control. CV1, CV2 and CV3 sequences are also seen within the spike glycoprotein of SARS-CoV2. The peptide sequences are offered in net peptide quantities in individual vials of 0.25 mg each. The peptide epitopes can be used in ELISPOT, cytokine and CTL assays. The sequences in the set are, CV1- VLNDILSRL CV2- NLNESLIDL CV3- FIAGLIAIV CV4- KLPDDFMGCV (+ve control) CV5- AYRPPNAPIL (-ve control)
This peptide sequence represents residues 319-335 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 319-335 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 336-347 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 336-347 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 348-357 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 348-357 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 352-365 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 352-365 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 371-394 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 371-394 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 395-430 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 395-430 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 513-520 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 513-520 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence represents residues 523-541 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2.
This peptide sequence represents residues 523-541 of the RBD (receptor binding domain) identified from the RefSeq (YP_009724390.1) from the spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence has residues 438-458 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2.
This peptide sequence has residues 450-473 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2.
This peptide sequence has residues 450-473 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus
This peptide sequence has residues 480-496 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2.
This peptide sequence has residues 480-496 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
This peptide sequence has residues 500-509 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2.
This peptide sequence has residues 500-509 obtained from the RBM (receptor binding motif: 437-508) identified within the RBD from the RefSeq (YP_009724390.1) of spike protein of SARS-CoV-2. The sequence is labeled with Biotin-LC at the C-terminus.
Identified from in silico studies, the set of 6 peptides offered are unique T-cell epitopes from the SARS-CoV-2 spike protein sequence. The peptide sequences are offered in net peptide quantities in individual vials of 0.25 mg each. The sequences in the set are, CV2-1 YLQPRTFLL CV2-2 GVYFASTEK CV2-3 KLPDDFTGCV CV2-4 SIIAYTMSL CV2-5 NYNYLYRLFR CV2-6 GYLQPRTFLL
This peptide sequence represents a furin-like cleavage site of the Spike (S) protein of the SARS-CoV-2 virus. The S protein must be likely cleaved at two sites, S1/S2 and S2 for viral entry into host cell. The sequence at the S1/S2 junction which contains a polybasic cleavage site (RR↓AR) represents the first cleavage site. This peptide has been labeled with QXL®520 and 5-FAM.
This peptide sequence represents a second furin-like cleavage site of the Spike (S) protein also thought to participate in the process of viral entry into host cell. The sequence at the S2 site (KR↓SF) contains two basic residues (P1 and P2) and a hydrophobic P3 residue. This site is identical between the SARS-CoV-2 and SARS-CoV. This peptide has been labeled with QXL®520 and 5-FAM.
Beclin-1 peptide is the HIV-1 Nef binding portion of full-length human Beclin-1 protein (amino acids 267-299). Beclin-1 protein is an autophagy inducing agent that may trigger cellular adaptation, survival or cell death. When conjugated to the cell-permeable peptide, it can successfully enter cells and induce autophagy. RELATED PRODUCTS:Beclin-1, Cat# 65466Tat-Beclin-1, scrambled, Cat# 65468
Tat - Beclin - 1, scrambled YGRKKRRQRRRGGVGNDFFINHETTGFATEW
Cat No.
AS-65468
규격
1 mg
제조사
Anaspec
제품정보
Beclin-1 peptide is the HIV-1 Nef binding portion of full-length human Beclin-1 protein (amino acids 267-299). Beclin-1 protein is an autophagy inducing agent that may trigger cellular adaptation, survival or cell death. When conjugated to the cell-permeable peptide, it can successfully enter cells and induce autophagy. Tat-Beclin-1, scrambled will not induce autophagy and can be used as a negative control. RELATED PRODUCTS:Tat-Beclin-1, Cat# 65467Beclin-1, Cat# 65466
The SensoLyte® 520 SARS-CoV-2 3CL Protease Activity Assay Kit employs a fluorescence FRET peptide substrate for the detection of enzyme activity. The sequence of this substrate is based on the site-specific cleavage sequence for coronavirus 3CLpro enzymes. When active 3CL Protease cleaves the FRET substrate, it results in an increase of HiLyte Fluor™ 488 green fluorescence monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, the HiLyte™ Fluor 488/QXL® 520 based FRET peptide has less interference from the autofluorescence of test compounds and cellular components and provides better assay sensitivity. This assay can detect as low as 15.6 ng/mL active 3CL protease in the sample. This kit can be used to detect enzyme activity in purified enzyme preparations, biological samples and can also be applied for compound screening. Kit size: 100 assays (96-well plate)
SensoLyte® 520 SARS - CoV - 2 Papain - like Protease/ De - ubiquitinase Activity Assay Kit
1 kit
Anaspec
The SensoLyte® 520 SARS-CoV-2 Papain-like Protease/ De-ubiquitinase Activity Assay Kit employs a fluorescence peptide substrate for the detection of de-ubiquitnation activity. When active Papain-like Protease cleaves the substrate, it results in an increase of bright green fluorescence at excitation/emission = 490 nm/520 nm. This assay can detect as low as 7.8 ng/mL active Papain-like Protease in the sample. This kit can be used to detect enzyme activity in purified enzyme preparations, biological samples and can also be applied for compound screening. Kit size: 100 assays (96-well plate)
An ACE-2 (Angiotensin I-converting enzyme 2) fluorescent substrate. Complete hydrolysis of 0.04 mM results in a 300-fold fluorescence increase over background. Max Abs/Em=325/393 nm upon cleavage of substrate.
The SensoLyte® Rh110 Furin Assay Kit provides a convenient assay for screening of enzyme inhibitors or for continuous assay of furin activity using a fluorogenic substrate. Upon cleavage by furin, this substrate generates the Rh110 (rhodamine 110) fluorophore with bright green fluorescence that can be detected at excitation/emission=490 nm/520 nm. The longer-wavelength spectra and higher extinction coefficient of the Rh110 provide greater sensitivity and less interference from other reaction components. The detection limit can reach as low as 0.02 ng/mL.
SensoLyte ® 520 Cathepsin B Assay Kit *Fluorimetric
1 kit
Anaspec
The SensoLyte® 520 Cathepsin B Activity Assay Kit provides a QXL® 520/HiLyte™ Fluor 488 labeled FRET peptide substrate for measurement of enzyme activity. In the intact FRET peptide, the fluorescence of HiLyte™ Fluor 488 is quenched by QXL® 520. Upon cleavage of the FRET peptide by the active enzyme, the increase of fluorescence can be continuously monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, the QXL® 520/HiLyte™ Fluor 488 based FRET peptide has less interference from the autofluorescence of test compounds and cellular components and provides better assay sensitivity. The kit can be used to detect the activity of Cathepsin B enzyme in biological samples and purified enzyme preparations. The kit contains: • QXL® 520/HiLyte™ Fluor 488-based FRET peptide substrate (Ex/Em=490/520 nm upon cleavage) • Assay buffer • Human liver Cathepsin B • Inhibitor • Fluorescence reference standard for calibration • A detailed protocol Kit size: 100 assays (96-well plate)
SensoLyte ® 440 Cathepsin B Assay Kit *Fluorimetric*
1 kit
Anaspec
The SensoLyte® 440 Cathepsin B Assay Kit provides a fluorogenic peptide for measurement of enzyme activity. This peptide releases the AMC (7-amino-4-methylcoumarin) fluorophore upon cathepsin B cleavage and can be detected with excitation at 354 nm and emission at 442 nm. The kit contains: • AMC based fluorogenic substrate (Ex/Em=354 nm/442 nm upon cleavage) • Assay buffer • Human liver Cathepsin B • Inhibitor • Fluorescence reference standard for calibration • A detailed protocol Kit size: 100 assays (96-well plate)
SensoLyte ® 520 Cathepsin L Assay Kit *Fluorimetric*
1 kit
Anaspec
The SensoLyte® 520 Cathepsin L Activity Assay Kit uses a QXL® 520/HiLyte™ Fluor 488 labeled FRET peptide substrate for measuring enzyme activity. The long wavelength FRET substrate is designed based on a sequence surrounding the cleavage site of Cathepsin L. The QXL® 520/HiLyte™ Fluor 488 pair is used for optimal quenching of the intact substrate. When active Cathepsin L cleaves the FRET substrate, it results in an increase of HiLyte™ Fluor 488 fluorescence and is monitored at excitation/emission = 490 nm/520 nm. The fluorescent signal from HiLyte™ Fluor 488 is stable at low pH, the optimal pH for Cathepsin L activity. Kit size: 100 assays (96-well plate)
SensoLyte ® Rh110 Cathepsin L Assay Kit *Fluorimetric*
1 kit
Anaspec
The SensoLyte® Rh110 Cathepsin L Activity Assay Kit provides a convenient assay for screening Cathepsin L inhibitors or assay of enzyme activity using a fluorogenic substrate. Upon cleavage by Cathepsin L, this substrate generates the Rh110 (rhodamine 110) fluorophore with a bright green fluorescence that can be detected at excitation/emission=490/520 nm. The longer wavelength spectra and higher extinction coefficient of Rh110 provide greater sensitivity and less interference from other reaction components. Kit size: 100 assays (96-well plate)
The SensoLyte® 520 SARS-CoV-2 3CL Protease Activity Assay Kit employs a fluorescence FRET peptide substrate for the detection of enzyme activity. The sequence of this substrate is based on the site-specific cleavage sequence for coronavirus 3CLpro enzymes. When active 3CL Protease cleaves the FRET substrate, it results in an increase of HiLyte Fluor™ 488 green fluorescence monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, the HiLyte™ Fluor 488/QXL® 520 based FRET peptide has less interference from the autofluorescence of test compounds and cellular components and provides better assay sensitivity. This assay can detect as low as 15.6 ng/mL active 3CL protease in the sample. This kit can be used to detect enzyme activity in purified enzyme preparations, biological samples and can also be applied for compound screening. Kit size: 100 assays (96-well plate)
SensoLyte® 520 SARS - CoV - 2 Papain - like Protease/ De - ubiquitinase Activity Assay Kit
Cat No.
AS-72263
규격
1 kit
제조사
Anaspec
제품정보
The SensoLyte® 520 SARS-CoV-2 Papain-like Protease/ De-ubiquitinase Activity Assay Kit employs a fluorescence peptide substrate for the detection of de-ubiquitnation activity. When active Papain-like Protease cleaves the substrate, it results in an increase of bright green fluorescence at excitation/emission = 490 nm/520 nm. This assay can detect as low as 7.8 ng/mL active Papain-like Protease in the sample. This kit can be used to detect enzyme activity in purified enzyme preparations, biological samples and can also be applied for compound screening. Kit size: 100 assays (96-well plate)
An ACE-2 (Angiotensin I-converting enzyme 2) fluorescent substrate. Complete hydrolysis of 0.04 mM results in a 300-fold fluorescence increase over background. Max Abs/Em=325/393 nm upon cleavage of substrate.
The SensoLyte® Rh110 Furin Assay Kit provides a convenient assay for screening of enzyme inhibitors or for continuous assay of furin activity using a fluorogenic substrate. Upon cleavage by furin, this substrate generates the Rh110 (rhodamine 110) fluorophore with bright green fluorescence that can be detected at excitation/emission=490 nm/520 nm. The longer-wavelength spectra and higher extinction coefficient of the Rh110 provide greater sensitivity and less interference from other reaction components. The detection limit can reach as low as 0.02 ng/mL.
SensoLyte ® 520 Cathepsin B Assay Kit *Fluorimetric
Cat No.
AS-72164
규격
1 kit
제조사
Anaspec
제품정보
The SensoLyte® 520 Cathepsin B Activity Assay Kit provides a QXL® 520/HiLyte™ Fluor 488 labeled FRET peptide substrate for measurement of enzyme activity. In the intact FRET peptide, the fluorescence of HiLyte™ Fluor 488 is quenched by QXL® 520. Upon cleavage of the FRET peptide by the active enzyme, the increase of fluorescence can be continuously monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, the QXL® 520/HiLyte™ Fluor 488 based FRET peptide has less interference from the autofluorescence of test compounds and cellular components and provides better assay sensitivity. The kit can be used to detect the activity of Cathepsin B enzyme in biological samples and purified enzyme preparations. The kit contains: • QXL® 520/HiLyte™ Fluor 488-based FRET peptide substrate (Ex/Em=490/520 nm upon cleavage) • Assay buffer • Human liver Cathepsin B • Inhibitor • Fluorescence reference standard for calibration • A detailed protocol Kit size: 100 assays (96-well plate)
SensoLyte ® 440 Cathepsin B Assay Kit *Fluorimetric*
Cat No.
AS-72165
규격
1 kit
제조사
Anaspec
제품정보
The SensoLyte® 440 Cathepsin B Assay Kit provides a fluorogenic peptide for measurement of enzyme activity. This peptide releases the AMC (7-amino-4-methylcoumarin) fluorophore upon cathepsin B cleavage and can be detected with excitation at 354 nm and emission at 442 nm. The kit contains: • AMC based fluorogenic substrate (Ex/Em=354 nm/442 nm upon cleavage) • Assay buffer • Human liver Cathepsin B • Inhibitor • Fluorescence reference standard for calibration • A detailed protocol Kit size: 100 assays (96-well plate)
SensoLyte ® 520 Cathepsin L Assay Kit *Fluorimetric*
Cat No.
AS-72218
규격
1 kit
제조사
Anaspec
제품정보
The SensoLyte® 520 Cathepsin L Activity Assay Kit uses a QXL® 520/HiLyte™ Fluor 488 labeled FRET peptide substrate for measuring enzyme activity. The long wavelength FRET substrate is designed based on a sequence surrounding the cleavage site of Cathepsin L. The QXL® 520/HiLyte™ Fluor 488 pair is used for optimal quenching of the intact substrate. When active Cathepsin L cleaves the FRET substrate, it results in an increase of HiLyte™ Fluor 488 fluorescence and is monitored at excitation/emission = 490 nm/520 nm. The fluorescent signal from HiLyte™ Fluor 488 is stable at low pH, the optimal pH for Cathepsin L activity. Kit size: 100 assays (96-well plate)
SensoLyte ® Rh110 Cathepsin L Assay Kit *Fluorimetric*
Cat No.
AS-72217
규격
1 kit
제조사
Anaspec
제품정보
The SensoLyte® Rh110 Cathepsin L Activity Assay Kit provides a convenient assay for screening Cathepsin L inhibitors or assay of enzyme activity using a fluorogenic substrate. Upon cleavage by Cathepsin L, this substrate generates the Rh110 (rhodamine 110) fluorophore with a bright green fluorescence that can be detected at excitation/emission=490/520 nm. The longer wavelength spectra and higher extinction coefficient of Rh110 provide greater sensitivity and less interference from other reaction components. Kit size: 100 assays (96-well plate)